Insights from 2023 ASH Annual Meeting


 

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo

151 views
March 22, 2024
Comments 0
Login to view comments. Click here to Login